Systemic high-dose intravenous methotrexate for central nervous system metastases

Journal of Neuro-Oncology

Volumn 78, Issue 3, 2006, Pages 255-260

  Lassman, Andrew B ^a   Abrey, Lauren E ^a   Shah, Gaurav G ^a   Panageas, Katherine S ^a   Begemann, Martin ^b   Malkin, Mark G ^c   Raizer, Jeffrey J ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Brain; Central nervous system; Chemotherapy; Leptomeninges; Metastases; Methotrexate

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CAPECITABINE; CREATININE; HEMOGLOBIN; METHOTREXATE; THIOTEPA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; BRAIN HYPOXIA; BRAIN RADIOGRAPHY; BREAST CANCER; CANCER CONTROL; CANCER GROWTH; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG CLEARANCE; DRUG FEVER; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HYPONATREMIA; KIDNEY FAILURE; LEUKOCYTE COUNT; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; MALE; MEDICAL RECORD; MENINGEAL METASTASIS; NEUTROPHIL; OVERALL SURVIVAL; PARENCHYMA; PLEURA EFFUSION; REVIEW; SEIZURE; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SQUAMOUS CELL CARCINOMA; THROMBOCYTE; THROMBOCYTOPENIA; TRANSAMINITIS; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CENTRAL NERVOUS SYSTEM NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33745768386     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-005-9044-6     Document Type: Review

References (17)

1. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI, 1999 Identification of prognostic factors in patients with brain metastases: A review of 1292 patients Int J Radiat Oncol Biol Phys 43: 795-803
2. Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P, Egorin MJ, 1998 High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary? J Clin Oncol 16: 1561-1567
3. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG, 2000 New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92: 205-216
4. Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG, 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8: 1277-1280
5. Begemann M, Rosenblum MK, Loh J, Kraus D, Raizer JJ, 2003 Leptomeningeal metastases from recurrent squamous cell cancer of the skin J Neurooncol 63: 295-298
6. Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF, Howell SB, 1999 A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors Clin Cancer Res 5: 3394-3402
7. Jaeckle KA, Batchelor T, O'Day SJ, Phuphanich S, New P, Lesser G, Cohn A, Gilbert M, Aiken R, Heros D, Rogers L, Wong E, Fulton D, Gutheil JC, Baidas S, Kennedy JM, Mason W, Moots P, Russell C, Swinnen LJ, Howell SB, 2002 An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis J Neurooncol 57: 231-239
8. Grossman SA, Finkelstein DM, Ruckdeschel JC, Trump DL, Moynihan T, Ettinger DS, 1993 Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis Eastern Cooperative Oncology Group J Clin Oncol 11: 561-569
9. Sandberg DI, Bilsky MH, Souweidane MM, Bzdil J, Gutin PH, 2000 Ommaya reservoirs for the treatment of leptomeningeal metastases Neurosurgery 47: 49-54
10. Lassman AB, DeAngelis LM, 2003 Brain metastases Neurol Clin 21: 1-23
11. Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, Malkin MG, 2001 A phase II trial of temozolomide for patients with recurrent or progressive brain metastases J Neurooncol 53: 259-265
12. Christodoulou C, Bafaloukos D, Kosmidis P, Samantas E, Bamias A, Papakostas P, Karabelis A, Bacoyiannis C, Skarlos DV, 2001 Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases Ann Oncol 12: 249-254
13. Siena S, Landonio E, Baietta E, Vitali M, Crino L, Danova M, Musolino A, Gardin G, Fao P, Fincato G, 2003 Multicenter phase II study of temozolomide therapy for brain metastasis in patients with malignant melanoma, breast cancer, and non-small cell lung cancer (Abstract 407) Proc Am Soc Clin Oncol 22: 102
14. Wong ET, Berkenblit A, 2004 The role of topotecan in the treatment of brain metastases Oncologist 9: 68-79
15. Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL, 2001 Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer Am J Clin Oncol 24: 421-424
16. Siegelmann-Danieli N, Stein M, Bar-Ziv J, 2003 Complete response of brain metastases originating in breast cancer to capecitabine therapy Isr Med Assoc J 5: 833-834
17. Posner JB: 1995 Neurologic complications of cancer F.A. Davis Company, Philadelphia, p 78